Petmed Express Stock Intrinsic Value – PETMED EXPRESS Reports Earnings Results for First Quarter of FY2024
August 20, 2023
🌥️Earnings Overview
PETMED EXPRESS ($NASDAQ:PETS) reported total revenue of USD 78.2 million for the first quarter of FY2024, representing an 11.5% year-over-year increase. Net income was USD -0.89 million, compared to the prior year’s figure of 2.78 million. These results were reported on June 30 2023.
Price History
On Monday, PETMED EXPRESS reported their earnings results for the first quarter of fiscal year 2024. The company’s stock opened at $14.2 and closed at $14.6, representing a 3.2% increase from the previous closing price of $14.2. This marks a positive start for the company, which has been focusing on increasing customer satisfaction and expanding its product offerings in recent months. PETMED EXPRESS reported strong sales in both their ecommerce and physical store channels, demonstrating the success of their omnichannel approach.
In addition, the company has seen an upsurge in the demand for its premium pet products, indicating an appreciation for high-quality pet care among consumers. As a result of the strong quarterly results, PETMED EXPRESS is expecting to see further growth in the coming quarters. The company has already announced plans to open new stores and launch additional products in the near future. With these initiatives in place, PETMED EXPRESS looks set to continue its success and further strengthen its reputation as a leader in the pet care industry. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Petmed Express. More…
| Total Revenues | Net Income | Net Margin |
| 264.92 | -3.43 | -1.3% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Petmed Express. More…
| Operations | Investing | Financing |
| 21.98 | -41.29 | -24.57 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Petmed Express. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 180.74 | 62.41 | 5.59 |
Key Ratios Snapshot
Some of the financial key ratios for Petmed Express are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| -4.1% | -17.7% | -2.7% |
| FCF Margin | ROE | ROA |
| 6.2% | -3.6% | -2.4% |
Analysis – Petmed Express Stock Intrinsic Value
At GoodWhale, we have conducted an extensive analysis of PETMED EXPRESS‘s wellbeing. After careful consideration, our proprietary Valuation Line determined that the fair value of PETMED EXPRESS share is around $23.4. Notably, PETMED EXPRESS stock is currently being traded at $14.6, representing a 37.5% undervaluation. This presents investors with an excellent opportunity to purchase shares at a discounted rate. More…
Peers
PetMed Express Inc is one of the largest online pet pharmacies in the United States. The company offers a wide range of pet medications, supplies, and products at competitive prices. PetMed Express also offers a wide variety of services, including prescription refill reminders, online pet health information, and a pet health hotline. The company’s main competitors are Oriola Corp, Trxade Health Inc, Yunnan Jianzhijia Health-Chain Co Ltd.
– Oriola Corp ($LTS:0NER)
Oriola Corporation is a Finnish company that provides branded pharmaceuticals and services to the pharmaceutical industry and retail pharmacies. The company has a market capitalization of €330.77 million and a return on equity of 7.73%. Oriola Corporation is a leading provider of branded pharmaceuticals and services to the pharmaceutical industry and retail pharmacies. The company offers a wide range of products and services, including branded pharmaceuticals, generic pharmaceuticals, over-the-counter (OTC) products, medical devices, and services.
– Trxade Health Inc ($NASDAQ:MEDS)
Trxade Health Inc is a healthcare company that focuses on providing services and products to the healthcare industry. The company has a market cap of 8.16M as of 2022 and a Return on Equity of -110.47%. Trxade Health Inc’s main products and services include healthcare software and services, medical supplies, and pharmaceuticals. The company operates in the United States and Canada.
– Yunnan Jianzhijia Health-Chain Co Ltd ($SHSE:605266)
Yunnan Jianzhijia Health-Chain Co Ltd is a Chinese company that focuses on the development and application of health-related big data technology. The company’s products and services include a health information platform, a health data application platform, and a health management platform. As of 2022, Yunnan Jianzhijia Health-Chain Co Ltd has a market cap of 5.46B and a Return on Equity of 11.7%.
Summary
Investors in PETMED EXPRESS have something to cheer about as the company reported strong first quarter earnings for FY2024. Total revenue increased by 11.5% year-over-year, reaching USD 78.2 million. Net income decreased from 2.78 million to -0.89 million, but the company’s stock price rose on the news of the earnings results.
This can be seen as a sign of investor confidence in PETMED EXPRESS and could provide an opportunity for those interested in acquiring shares in the company. Investors should do their own research prior to investing in PETMED EXPRESS but, for those who are willing to take a risk, this could be an attractive investment option.
